Post-transplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT). Given the heterogeneity of PTLD and the risk of infectious complications in immunosuppressed patients, treatment of this disease remains challenging. Monomorphic PTLD and lymphoma of B-cell origin account for the majority of cases. Treatment strategies for PTLD consist of response-adapted …